enGene Announces Offering of Common Shares, Amount Not Disclosed

Written by Emily J. Thompson, Senior Investment Analyst

ENGN-6.33%

Updated: Nov 12 2025

0mins

Public Offering Announcement: enGene Holdings has initiated an underwritten public offering of its common shares.
Share Offering Details: All common shares in the offering will be sold by enGene itself.
Management Team: Jefferies, Leerink Partners, and Wells Fargo Securities are serving as joint book running managers for the offering.
Purpose of Offering: The announcement indicates a strategic move by enGene to raise capital through the sale of its shares.

ENGN

$11.4+Infinity%1D

Analyst Views on ENGN

Wall Street analysts forecast ENGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENGN is 23.75 USD with a low forecast of 10.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Analyst Rating

7 Buy

1 Hold

0 Sell

Strong Buy

Current: 12.170

Low

10.00

Averages

23.75

High

33.00

Current: 12.170

Low

10.00

Averages

23.75

High

33.00

UBS

Neutral

maintain

$4 -> $10

2025-11-12

Reason

UBS

Price Target

$4 -> $10

AI Analysis

2025-11-12

maintain

Neutral

Reason

UBS raised the firm's price target on enGene (ENGN) to $10 from $4 and keeps a Neutral rating on the shares. EnGene reported updated Phase 2 LEGEND trial data for detalimogene in high-risk BCG-unresponsive non-muscle invasive bladder cancer, showing a 63% anytime complete response rate and 62% six-month CR under the amended protocol, an improvement from prior results but below competitors CG Oncology (CGON) and Johnson & Johnson (JNJ), the analyst tells investors in a research note. While the results confirm deta's activity, limited near-term catalysts and a later market entry contribute to a Neutral outlook.

Oppenheimer

Outperform

maintain

$30 -> $33

2025-11-12

Reason

Oppenheimer

Price Target

$30 -> $33

2025-11-12

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on enGene to $33 from $30 and keeps an Outperform rating on the shares. The firm believes the reveal from the pivotal LEGEND trial in high-risk NMIBC is not only impressive in its own right - highlighted by detalimogene's 62% 6-month complete response rate - but also addresses the market's skepticism following last September's initial showing, which preceded changes that brought the trial's design closer to current standards for this indication.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ENGN

Unlock Now

Morgan Stanley

Overweight

maintain

$18 -> $19

2025-11-12

Reason

Morgan Stanley

Price Target

$18 -> $19

2025-11-12

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on enGene to $19 from $18 and keeps an Overweight rating on the shares after the company provided updated data from the pivotal cohort of its Phase 2 LEGEND trial, investigating its non-viral gene therapy detalimogene in Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer patients. Detalimogene's profile appears competitive with other NMIBC agents and 6-month CR was the "standout measure," says the analyst, who sees the update improving detalimogene's product profile.

Citizens JMP

Silvan Tuerkcan

Outperform

maintain

$18 -> $21

2025-11-12

Reason

Citizens JMP

Silvan Tuerkcan

Price Target

$18 -> $21

2025-11-12

maintain

Outperform

Reason

Citizens JMP analyst Silvan Tuerkcan raised the firm's price target on enGene to $21 from $18 and keeps an Outperform rating on the shares. Citizens was impressed by the speed of enrollment in enGene's LEGEND trial and the substantially higher complete response rate following protocol amendments that harmonized LEGEND with other newer non-muscle invasive bladder cancer assets, the analyst tells investors in a research note. EnGene has demonstrated that detalimogene is comparable to best-in-class assets on six-month CR, and the update puts detalimogene in the range of the most efficacious therapies, removing the efficacy barrier, the firm says.

About ENGN

enGene Holdings Inc. is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The Company is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.